SAB Biotherapeutics, Inc.

Contributing Author

Recent Articles by SAB Biotherapeutics, Inc.

Apr-15	SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress SABS GlobeNewswire
Mar-19	SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants SABS GlobeNewswire
Mar-17	SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants SABS -9.09% GlobeNewswire
Mar-17	SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants SABS -9.09% SABS GlobeNewswire
Mar-10	SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes SABS +6.77% GlobeNewswire
Mar-09	SAB BIO Reports Full Year 2025 Financial Results and Business Highlights SABS GlobeNewswire
Mar-02	SAB BIO to Participate in Upcoming Investor Conferences SABS GlobeNewswire
Feb-04	SAB BIO to Participate in Upcoming Investor Conferences SABS GlobeNewswire
Jan-07	SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director SABS +9.67% GlobeNewswire
Jan-06	SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference SABS GlobeNewswire
Dec-18	First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D SABS GlobeNewswire
Dec-17	SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D SABS GlobeNewswire
Dec-08	SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management SABS -10.80% GlobeNewswire
Nov-13	SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights SABS -9.09% GlobeNewswire
Nov-04	SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 SABS GlobeNewswire
Nov-04	SAB BIO to Participate in Upcoming Investor Conferences SABS GlobeNewswire
Sep-19	SAB BIO Highlights Data in Multiple Presentations at EASD SABS -11.47% GlobeNewswire
Sep-03	SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes SABS +9.43% GlobeNewswire
Aug-07	SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates SABS GlobeNewswire
Jul-21	SAB BIO Announces Oversubscribed $175 Million Private Placement SABS +5.06% GlobeNewswire
May-09	SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates SABS GlobeNewswire

SAB Biotherapeutics, Inc.

Recent Articles by SAB Biotherapeutics, Inc.

Upgrade your Finviz experience